Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey

被引:60
作者
Kotronen, Anna [1 ,2 ,3 ]
Yki-Jarvinen, Hannele [2 ]
Mannisto, Satu [4 ]
Saarikoski, Liisa [1 ]
Korpi-Hyovalti, Eeva [5 ]
Oksa, Heikki [6 ]
Saltevo, Juha [7 ]
Saaristo, Timo [6 ]
Sundvall, Jouko [8 ]
Tuomilehto, Jaakko [9 ]
Peltonen, Markku [1 ]
机构
[1] Natl Inst Hlth & Welf, Diabet Prevent Unit, Helsinki, Finland
[2] Univ Helsinki, Dept Med, Div Diabet, Helsinki, Finland
[3] Minerva Med Res Inst, Helsinki, Finland
[4] Natl Inst Hlth & Welf, Dept Chron Dis Prevent, Helsinki, Finland
[5] S Ostrobothnia Cent Hosp, Dept Internal Med, Seinajoki, Finland
[6] Tampere Univ Hosp, Tampere, Finland
[7] Cent Finland Cent Hosp, Dept Internal Med, Jyvaskyla, Finland
[8] Natl Inst Hlth & Welf, Lab Analyt Biochem, Dept Hlth & Funct Capac, Helsinki, Finland
[9] Univ Helsinki, Dept Publ Hlth, FIN-00014 Helsinki, Finland
基金
芬兰科学院;
关键词
ALANINE AMINOTRANSFERASE; INSULIN-RESISTANCE; PREVALENCE; STEATOHEPATITIS; DIAGNOSIS; PROGNOSIS; MARKERS; PLASMA; RISK;
D O I
10.1186/1471-2458-10-237
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background: Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods: The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results: Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). Discussion and conclusion: In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.
引用
收藏
页数:7
相关论文
共 30 条
[1]   The metabolic syndrome - a new worldwide definition [J].
Alberti, KGMM ;
Zimmet, P ;
Shaw, J .
LANCET, 2005, 366 (9491) :1059-1062
[2]   The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD [J].
Angulo, Paul ;
Hui, Jason M. ;
Marchesini, Giulio ;
Bugianesi, Ellisabetta ;
George, Jacob ;
Farrell, Geoffrey C. ;
Enders, Felicity ;
Saksena, Sushma ;
Burt, Alastair D. ;
Bida, John P. ;
Lindor, Keith ;
Sanderson, Schuyler O. ;
Lenzi, Marco ;
Adams, Leon A. ;
Kench, James ;
Therneau, Terry M. ;
Day, Christopher P. .
HEPATOLOGY, 2007, 45 (04) :846-854
[3]  
[Anonymous], 992 WHO 1
[4]   Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study [J].
Bedogni, G ;
Miglioli, L ;
Masutti, F ;
Tiribelli, C ;
Marchesini, G ;
Bellentani, S .
HEPATOLOGY, 2005, 42 (01) :44-52
[5]   Plasma adiponectin in nonalcoholic fatty liver is related to hepatic insulin resistance and hepatic fat content, not to liver disease severity [J].
Bugianesi, E ;
Pagotto, U ;
Manini, R ;
Vanni, E ;
Gastaldelli, A ;
de Iasio, R ;
Gentilcore, E ;
Natale, S ;
Cassader, M ;
Rizzetto, M ;
Pasquali, R ;
Marchesini, G .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2005, 90 (06) :3498-3504
[6]  
Clark JM, 2006, J CLIN GASTROENTEROL, V40, pS5
[7]  
Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
[8]  
CLUETTE JE, 1984, P SOC EXP BIOL MED, V176, P508, DOI 10.3181/00379727-176-4-RC2
[9]   Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course [J].
Cortez-Pinto, H ;
Camilo, ME .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2004, 18 (06) :1089-1104
[10]   Long term prognosis of fatty liver: risk of chronic liver disease and death [J].
Dam-Larsen, S ;
Franzmann, M ;
Andersen, IB ;
Christoffersen, P ;
Jensen, LB ;
Sorensen, TIA ;
Becker, U ;
Bendtsen, F .
GUT, 2004, 53 (05) :750-755